BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

935 related articles for article (PubMed ID: 14994384)

  • 1. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
    Kubota A; Hasegawa K; Suguro T; Koshihara Y
    J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
    Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
    Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
    Dai SM; Nishioka K; Yudoh K
    Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N; Maeda H; Yoshimine Y; Akamine A
    Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls.
    Vanderborght A; Linsen L; Thewissen M; Geusens P; Raus J; Stinissen P
    J Rheumatol; 2004 Aug; 31(8):1483-90. PubMed ID: 15290725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.
    Kotake S; Udagawa N; Hakoda M; Mogi M; Yano K; Tsuda E; Takahashi K; Furuya T; Ishiyama S; Kim KJ; Saito S; Nishikawa T; Takahashi N; Togari A; Tomatsu T; Suda T; Kamatani N
    Arthritis Rheum; 2001 May; 44(5):1003-12. PubMed ID: 11352231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of synovial cell clones isolated from rheumatoid arthritis patients: possible involvement of TNF-alpha in reduction of osteoprotegerin in synovium.
    Zhao B; Takami M; Miyamoto Y; Suzawa T; Yamada A; Mochizuki A; Yasuhara R; Wang X; Inoue T; Namiki O; Sakamoto K; Kamijo R
    Cytokine; 2008 Jan; 41(1):61-70. PubMed ID: 18083042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils.
    Poubelle PE; Chakravarti A; Fernandes MJ; Doiron K; Marceau AA
    Arthritis Res Ther; 2007; 9(2):R25. PubMed ID: 17341304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium.
    Hou WS; Li W; Keyszer G; Weber E; Levy R; Klein MJ; Gravallese EM; Goldring SR; Brömme D
    Arthritis Rheum; 2002 Mar; 46(3):663-74. PubMed ID: 11920402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic implications for interferon-alpha in arthritis: a pilot study.
    Wong T; Majchrzak B; Bogoch E; Keystone EC; Fish EN
    J Rheumatol; 2003 May; 30(5):934-40. PubMed ID: 12734885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of intercellular adhesion molecule-1 expression on human synovial fibroblasts by endothelin-1.
    Iwabuchi H; Kasama T; Hanaoka R; Miwa Y; Hatano Y; Kobayashi K; Mori Y; Negishi M; Ide H; Adachi M
    J Rheumatol; 1999 Mar; 26(3):522-31. PubMed ID: 10090156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
    J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
    Makrygiannakis D; af Klint E; Catrina SB; Botusan IR; Klareskog E; Klareskog L; Ulfgren AK; Catrina AI
    Arthritis Rheum; 2006 May; 54(5):1463-72. PubMed ID: 16646024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
    Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response.
    Marotte H; Maslinski W; Miossec P
    Arthritis Res Ther; 2005; 7(1):R149-55. PubMed ID: 15642135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients.
    Harashima SI; Tsukamoto H; Horiuchi T
    Rheumatology (Oxford); 2004 Mar; 43(3):396-7; author reply 397. PubMed ID: 14963213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 47.